ORTX — Orchard Therapeutics Share News
0.000.00%
Last trade - 00:00- $378.06m
- $278.24m
- $22.66m
U.S. STOCKS ON THE MOVE-Pfizer, Hewlett Packard, BioNTech, Amarin
Orchard Therapeutics rises after EU panel endorses co's gene therapy
Brief: Orchard Therapeutics Receives Positive CHMP Opinion For Libmeldy
Brief: Orchard Therapeutics Receives EMA Prime Designation For Otl-203 For Treatment Of Mps-I
Brief: Orchard Announces Additional Interim Results From Proof-Of-Concept Study Of OTL-203 For MPS-I
Brief: Orchard Therapeutics Posts Quarterly Loss Per Share 48 Cents
Brief: Orchard Therapeutics Announces Orphan Drug, Rare Pediatric Disease Designations For Otl-203 For Treatment Of MPS-I
Brief: Orchard Therapeutics Announces Global License Agreements For Stable Cell Line Technology From GSK
Brief: Orchard Therapeutics And Molmed Announce Extension Of Gene Therapy Manufacturing Collaboration
U.S. RESEARCH ROUNDUP- Martin Marietta Materials, ONEOK, Superior Energy Services
Brief: Orchard Therapeutics Reports New Interim Data From Study For MPS-I
Brief: Orchard Therapeutics Announces First Patient Dosed With Otl-201 Gene Therapy In Proof-Of-Concept Clinical Trial For Sanfilippo Syndrome
Brief: Orchard Therapeutics Says Still Preparing For Potential Approval For OTL-200 In 2020
Brief: Orchard Therapeutics Appoints Company Founder Bobby Gaspar As New Chief Executive Officer
Brief: Orchard Therapeutics Reports Qtrly Loss Per Share $0.46
Brief: Orchard Therapeutics Appoints Industry Veteran Steven Altschuler To Its Board Of Directors
Brief: Orchard Therapeutics Sees Its Cash, Cash Equivalents And Marketable Securities As Of Dec. 31, 2019 Will Enable Co To Fund Itself Into H1 Of 2021
U.S. RESEARCH ROUNDUP-Amphenol,Horizon Therapeutics, Perficient
Gene therapy developers rise on Astellas' $3 bln deal for Audentes